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The extracellular enveloped virus (EEV) form of vaccinia virus (VACV) is surrounded by two lipid
envelopes. This presents a topological problem for virus entry into cells, because a classical fusion
event would only release a virion surrounded by a single envelope into the cell. Recently, we
described a mechanism in which the EEV outer membrane is disrupted following interaction with
glycosaminoglycans (GAGs) on the cell surface and thus allowing fusion of the inner membrane
with the plasma membrane and penetration of a naked core into the cytosol. Here we show that
both the B5 and A34 viral glycoproteins are required for this process. A34 is required to recruit
B5 into the EEV membrane and B5 acts as a molecular switch to control EEV membrane rupture
upon exposure to GAGs. Analysis of VACV strains expressing mutated B5 proteins demonstrated
that the acidic stalk region between the transmembrane anchor sequence and the fourth short
consensus repeat of B5 are critical for GAG-induced membrane rupture. Furthermore, the
interaction between B5 and A34 can be disrupted by the addition of polyanions (GAGs) and
polycations, but only the former induce membrane rupture. Based on these data we propose a
revised model for EEV entry.
INTRODUCTION
Vaccinia virus (VACV) is the prototypical member of the
genus Orthopoxvirus of the Poxviridae (Moss, 2007). Like
other poxviruses, VACV replicates in the cytoplasm,
encodes many transcriptional enzymes (Broyles, 2003)
and produces multiple forms of virion (Smith et al., 2002;
Condit et al., 2006; Roberts & Smith, 2008). The first
infectious virion produced is called intracellular mature
virus (IMV). IMV represent the majority of infectious
progeny and each virion is surrounded by a single lipid
envelope (Dales & Siminovitch, 1961; Hollinshead et al.,
1999). Some IMV are transported on microtubules from
virus factories to near the microtubule organizing centre
where they are wrapped by two cellular membranes
containing several virus proteins. This produces a triple-
enveloped virus called intracellular enveloped virus (IEV).
IEV are transported on microtubules to the cell surface
where the outer membrane fuses with the plasma
membrane to externalise a double-enveloped virion by
exocytosis. This virion is called cell-associated enveloped
virus (CEV) or extracellular enveloped virus (EEV) if it is
released from the cell. Some authors refer to IMV, IEV and
CEV/EEV as mature virus (MV), wrapped virus (WV) and
extracellular virus (EV), respectively (Moss, 2006).
VACV entry is complicated by the existence of structurally
distinct virions surrounded by different numbers of
membranes and which bind to different receptors
(Vanderplasschen & Smith, 1997). IMV enter cells by
fusion with the plasma membrane (Armstrong et al., 1973;
Chang & Metz, 1976; Carter et al., 2005) or endocytosis
followed by fusion with an intracellular vesicle (Dales,
1963; Payne & Norrby, 1978; Townsley et al., 2006;
Townsley & Moss, 2007; Mercer & Helenius, 2008).
However, for EEV a fusion event would only release a
single enveloped virus into the cytosol and so replication
could not start until the second lipid envelope is removed.
Two solutions to this topological difficulty have been
suggested. First, after endocytosis, the EEV outer envelope
is disrupted by low pH within acidified vesicles, allowing
the IMV to fuse with the vesicle membrane (Ichihashi,
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of EEV with the cell surface induces non-fusogenic
disruption of the EEV outer membrane (Law et al.,
2006). This rupture occurs only at the site of interaction
between the plasma membrane and the virus particle, and
requires cell surface glycosaminoglycans (GAGs) and the
EEV proteins B5 and A34. After EEV outer membrane
rupture, the internal IMV particle fuses with the plasma
membrane to release a core into the cytosol. Probably, both
mechanisms operate, since EEV were not ruptured on the
surface of sog9 cells, which are deficient in cell surface
GAGs, yet EEV still infect these cells and form plaques
(Law et al., 2006). Cores are then transported deeper into
the cell on microtubules (Carter et al., 2005).
Here the mechanism by which the EEV outer membrane is
disrupted upon contact with the plasma membrane has
been investigated further. We focused on the B5 protein
because B5-negative EEV are resistant to GAG-mediated
EEV membrane rupture (Law et al., 2006).
B5 is a 42 kDa glycoprotein present in the EEV outer
membrane with type I topology (Engelstad et al., 1992;
Isaacs et al., 1992). The extracellular domain of B5
comprises four copies of a short consensus repeat (SCR)
characteristic of complement control proteins (Takahashi-
Nishimaki et al., 1991). However, there is no evidence that
B5 serves to regulate complement activity, and VACV
encodes a second protein with SCRs that inhibits
complement activation (Kotwal & Moss, 1988; Kotwal
et al., 1990). After these SCRs, B5 has an acidic stalk (ST)
region before the transmembrane (TM) sequence and short
cytoplasmic tail (CT). The SCRs are dispensable for
targeting the B5 protein to the EEV membrane, but their
deletion enhanced EEV release (Herrera et al., 1998;
Mathew et al., 1998). The CT is dispensable for incorpora-
tion of B5 into EEV (Lorenzo et al., 1998), but affects the
rate of B5 transport to the cell surface (Mathew et al., 2001)
and recycling from the cell surface via endosomes (Ward &
Moss, 2000). B5 is required for IMV wrapping to form IEV
(Engelstad & Smith, 1993; Wolffe et al., 1993). In addition,
B5 interacts with A34 (Rottger et al., 1999) and A34 is
required for the efficient incorporation of B5 into IEV/EEV
(Earley et al., 2008; Perdiguero et al., 2008).
A34 is a type II membrane protein with different glyco-
forms of between 23 and 28 kDa (Duncan & Smith, 1992).
It is expressed late during infection and is present on the
cell and EEV surface. There is an N-terminal single
transmembrane domain that serves as signal sequence
and membrane anchor, and an extracellular C-type lectin-
like domain (Duncan & Smith, 1992). Deletion of the A34R
gene (McIntosh & Smith, 1996) or a lys151glu mutation
(Blasco et al., 1993) enhanced EEV production. However,
A34-negative virions have a fivefold reduced specific
infectivity (McIntosh & Smith, 1996), form a small plaque
(Duncan & Smith, 1992), do not form actin tails (Wolffe
et al., 1997; Sanderson et al., 1998) and are avirulent
(McIntosh & Smith, 1996).
Here we investigated the role of B5 domains in EEV
membrane rupture and show that acidic residues in the ST
(amino acids 241–279) proximal to the EEV membrane are
critical for membrane rupture. Based on these data, a
refined model for EEV entry is presented.
METHODS
Cells. BSC-1, CV-1 and D98OR cells were grown in Dulbecco’s
modified Eagle’s medium (Gibco) supplemented with 10% fetal
bovine serum (FBS) and 50 IU penicillin ml
21–50 mg streptomy-
cin ml
21 (PS; Gibco). RK13 cells were grown in minimal essential
medium (MEM, Gibco) with 10% FBS, 2 mM L-glutamine (Gibco)
and PS. BHK-21 cells were grown in Glasgow-MEM (Sigma) with
10% FBS, 5% tryptose phosphate broth (Sigma), 2 mM L-glutamine
and PS. Alternatively, BHK-21 were grown in MEM with 10% FBS,
81 mg MEM non-essential amino acids l
21 (Sigma), 2 mM
L-glutamine, 16 vitamins (Gibco) and PS.
Antibodies. For immunoprecipitation, a rat monoclonal antibody
(mAb), anti-B5 19C2 (Schmelz et al., 1994), was used. To detect B5 by
immunoblotting, 19C2 or a mouse mAb 36-6 were used. mAb
directed against A34 (34-1), A36 [6.3, (van Eijl et al., 2000)] and D8
[AB1.1, (Parkinson & Smith, 1994)] were also used. For plaque-
reduction assays, Abs that neutralize IMV were either mAb 2D5
against the L1 protein (Ichihashi et al., 1994) or a polyclonal mix of
rabbit Abs against L1 and A27 (IMV-N serum).
GAGs and polyions. The following polyionic compounds were
tested for their ability to rupture the EEV outer membrane: poly-DL-
alanine (P9003), heparin, poly-L-aspartic acid sodium salt (P5387),
poly-L-histidine (P9386), poly-L-lysine hydrobromide (P0899) and
chitosan (C3646) (all from Sigma-Aldrich); dextran sulphate (31404)
and poly-L-glutamic acid (81326) from Fluka. Stock solutions (10 mg
ml
21) of these compounds were prepared in water or 1 M acetic acid
(chitosan).
Plasmids. Mutations were introduced into the B5R gene by site-
directed mutagenesis, PCR, splice overlap extension (Horton et al.,
1990) and gene cloning with the oligonucleotide primers described in
Supplementary Table S1 (available in JGV Online) and DNA from
VACV strain Western Reserve (WR) as template.
pB5R-STD1–19 aa. To delete the nucleotides within the B5R ORF
that encode the N-terminal half of the ST (amino acids 241–259 of the
B5 protein, or amino acids 1–19 of the ST), oligonucleotides B5-1 and
B5-3 were used to amplify the 59 flanking region of the B5R ORF and
the 59 end of the B5R ORF up to the start of the ST. Oligonucleotides
B5-4 and B5-2 were used to amplify the C-terminal half of the ST,
TM, CT and the 39 flanking region of the B5R ORF. Both fragments
were assembled into a 1537 bp gene using splice overlap extension
with oligonucleotides B5-1 and B5-2, cloned into pGEM and
subcloned into XbaI- and HindIII-digested pSJH7 (Hughes et al.,
1991) to form pB5R-STD1–19 aa.
pB5R-STD20–39 aa. To delete the nucleotides within the B5R ORF
that encode the C-terminal half of the ST (amino acids 20–39), PCR
was used as follows: oligonucleotides B5-1 and B5-5 were used to
amplify the B5R 59 flanking region and the 59 end of the B5R ORF up
to the N-terminal half of the ST. Oligonucleotides B5-6 and B5-2 were
used to amplify the B5R TM, CT and the 39 flanking region. Both
fragments were assembled into a single 1533 bp gene using splice
overlap extension with oligonucleotides B5-1 and B5-2, cloned into
pGEM and subcloned into XbaI- and HindIII-digested pSJH7
(Hughes et al., 1991) to form pB5R-STD20–39 aa.
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acidic amino acids within the B5 ST replaced by alanine residues were
constructed using the QuikChange PCR-based site-directed
mutagenesis kit (Stratagene). A plasmid derived from pSJH7
(pB5R) containing a 2016 bp fragment encoding the entire B5R
ORF with 429 bp upstream and 636 bp downstream was used as a
template. The nine N-terminal acidic residues (amino acids 2, 3, 5, 8,
9, 12, 13, 14 and 16, Fig. 3a) were converted to alanines using pB5R
and primers B5-A and B5-B to form pB5R-ST2–16ala. Similarly, the
five C-terminal acidic residues (amino acids 23, 28, 30, 32 and 35)
were mutated to alanines using oligonucleotides B5-C and B5-D to
form pB5R-ST23–35ala. Then all acidic residues within the B5 ST
were changed to alanines by sequential rounds of mutagenesis using
the above oligonucleotides to form pB5R-ST2–35ala. Next, one or
more acidic residues adjacent to the TM domain were mutated: (i)
E35A (pB5R-ST35ala) using primers B5-E and B5-F; (ii) E32A and
E35A (pB5R-ST32–35ala) using primers B5-G and B5-H; (iii) E30A,
E32A and E35A (pB5R-ST30–35ala) using primers B5-I and B5-J; and
(iv) E28A, E30A, E32A and E35A (pB5R-ST28–35ala) using primers
B5-K and B5-L; and (v) E28A and E30A (pB5R-ST28–30ala) using
primers B5-M and B5-N (Fig. 4a).
Recombinant viruses. Viruses lacking B5 SCR2-4, SCR 3-4, SCR 4
or all four SCRs and those with the B5 domains swapped with those
from A56 have been described previously (Herrera et al., 1998;
Mathew et al., 1998, 2001). Recombinant viruses containing the
additional B5 ST mutations described above were made by transient
dominant selection as described previously (Rodger & Smith, 2002).
Plaque reduction assay. Fresh EEV from the supernatant of
infected cells was clarified by centrifugation for 10 min at 1000 g,
4 uC. This was mixed with an equal volume of medium with or
without GAGs and incubated with the IMV-neutralizing antibody
(IMV-NAb) for 1 h at 37 uC. The mixture was adsorbed onto BS-C-1
cells for 90 min at 37 uC. Unbound virus and the Ab mixture were
washed away and cells were overlaid with DMEM/2.5% FBS and
1.5% carboxymethylcellulose. The cells were incubated for 2–4 days,
stained with crystal violet and the plaques were counted.
Preparation of cell lysates and EEV lysates. RK13 or BHK-21
cells were infected with viruses at 3–5 p.f.u. per cell for 24 h. Cells
were washed in PBS, harvested and lysed with Triton/NP-40 lysis
buffer (Rottger et al., 1999) for 20–30 min at 4 uC. Insoluble material
was centrifuged at 16000 g for 20 min. The supernatant containing
the cell extracts was frozen at 280 uC. To prepare EEV lysates, the
supernatant from infected cells was harvested 24 h post-infection,
centrifuged for 10 min at 1000 g,4uC to remove detached cells and
debris and then centrifuged for 2 h at 18000 g,4uC to collect virions.
The pellet containing EEV was resuspended in Triton/NP-40 lysis
buffer (Rottger et al., 1999). Lysates were aliquoted and stored at
280 uC. The protein concentration of the lysates was determined by
Bradford assay, using BSA as a standard.
Immunoprecipitation. EEV lysates were pre-cleared by incubation
for at least 10 min at 4 uC with Fast Flow 4 protein G Sepharose (GE
Healthcare). Lysates were then incubated with GAGs or polycations
for 10 min at room temperature followed by incubation with protein
G Sepharose beads cross-linked to rat mAb 19C2 (anti-B5) overnight
at 4 uC. Beads were washed extensively with lysis buffer and bound
proteins were eluted in 16 SDS sample buffer (50 mM Tris/HCl
pH 6.8, 2% SDS, 10% glycerol, 0.1% bromophenol blue, 10 mM b-
mercaptoethanol).
Immunoblotting. Samples were mixed with SDS sample buffer and
resolved by SDS-PAGE (15% gel), followed by semi-dry transfer on
Hybond enhanced chemiluminescence (ECL) or Hybond-P mem-
branes (GE Healthcare). Membranes were blocked for 2–4 h at room
temperature or overnight at 4 uC in PBS/0.1% Tween20 (PBS-T)
with 5% skim milk and then incubated for 2–15 h in primary
antibody diluted in PBS-T/1% milk. After extensive washes with PBS-
T, the membranes were incubated with anti-mouse-horseradish
peroxidase (Sigma) 1:2000 in PBS-T/1% milk for 1 h at room
temperature. Membranes were washed again with PBS-T and stained
with ECL+ (GE Healthcare) or home-made ECL before exposure of
X-ray films.
RESULTS
The absence of A34 leads to a defect of B5
incorporation into EEV
EEV lacking either B5 or A34 are resistant to GAG-induced
disruption (Law et al., 2006). This indicated that either
both proteins were needed, or that loss of one protein
affected incorporation of the other. Accordingly, we
purified EEV from wild-type (WT) virus, or viruses lacking
gene A34R or A33R and analysed the protein composition
by immunoblotting. The IMV surface protein D8 and the
EEV protein F13 were present at equal levels in all viruses,
but B5 was reduced considerably in the absence of A34, but
not A33 (Fig. 1a). These data are in accord with other
observations that A34 is required for the efficient
recruitment of B5 to the EEV membrane (Earley et al.,
2008; Perdiguero et al., 2008).
The EEV membrane is more stable in the absence
of A34 or B5
To test if loss of either B5 or A34 affected EEV membrane
stability, fresh EEV was produced with WR, vDB5R
(Engelstad & Smith, 1993) and vDA34R (McIntosh &
Smith, 1996). A fraction of each virus was incubated with
and without IMV-NAb followed by plaque assay to
determine the proportion of virus with an intact EEV
membrane. The remaining supernatant was stored at 4 uC
for 7, 14 and 21 days and then was retitrated as before. Fig.
1(b) shows that the proportion of WT (WR) EEV with an
intact outer membrane decreased with time whilst the
proportion of vDB5R and vDA34R remained relatively
constant. Thus, in the absence of B5 or A34 (which also
results in the reduction of B5) the EEV membrane is more
stable than that of the WT.
GAG-mediated rupture of the EEV membrane is
affected by their charge and structure
Incubation of EEV with polyanions (PAs) such as heparin
(HP) or dextran sulphate (DS) disrupts the EEV mem-
brane and makes virions sensitive to IMV-NAb (Law et al.,
2006). To ascertain the relative importance of the ionic
charge and carbohydrate structure of PAs in this process,
WT VACV strain WR EEV was incubated with a range of
ionic compounds comprised of amino acid subunits. The
anionic compounds poly-L-glutamic acid and poly-L-
aspartic acid (described previously by Law et al., 2006)
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and poly-D-lysine, and with poly-DL-alanine and DS as
controls. As expected, treatment of EEV with 5 mgD Sm l
21
and IMV-NAb reduced EEV infectivity to below the limit of
detection (4610
5 p.f.u. ml
21); however, none of the other
poly-ionic compounds had a substantial effect on EEV
infectivity (Fig. 1c and Law et al., 2006). The molecular
masses of these compounds varied considerably, producing
different charge to mass ratios, and this might affect EEV
membrane stability. To address this, EEV was incubated
with a much higher concentration (250 mgm l
21) of these
compounds. At this concentration, DS and IMV-NAb
inhibited all EEV infectivity whilst the other compounds
had little effect (Fig. 1d). The effect observed in the presence
of poly-D-lysine is unclear because it also reduces IMV
infectivity (data not shown). Collectively, these data suggest
that both the negative charge and the carbohydrate structure
of GAGs are required for efficient EEV membrane rupture.
B5 TM and ST are involved in GAG-induced
rupture of the EEV membrane
To investigate which B5 domain(s) is (are) involved in EEV
membrane rupture, EEV produced by a panel of viruses
with mutated B5 proteins (Fig. 2a) were tested for their
sensitivity to GAG-mediated membrane rupture. Some of
the viruses have one or more SCRs deleted (Herrera et al.,
1998; Mathew et al., 1998), others have sections of B5
substituted with the equivalent regions of the VACV WR
A56 (haemagglutinin, HA) protein (Mathew et al., 2001).
Viruses with one or more SCR deleted or with the CT
swapped with the A56 CT had the same phenotype as WT
WR and were sensitive to PA-induced EEV membrane
disruption (Fig. 2b), suggesting that the ST or TM regulates
EEV membrane rupture. Consistent with this, the TM is
implicated because vBR-A56ST/TM/CT is resistant to
GAGs. This is supported further by vB5-A56EC (in which
the BR SCRs are replaced by the ectodomain, EC, of A56)
and vB5-A56EC/TM (in which all B5 except the CT is
replaced by A56). The presence of B5 CT alone (vB5-
A56EC/TM) does not make the membrane sensitive to
GAGs, whereas the presence of B5 TM (and CT) (vB5-
A56EC) has an intermediate phenotype. Collectively, these
B5 mutants indicate that the B5 SCRs and CT are not
involved in EEV membrane rupture.
Role of the B5 ST acidic residues in the EEV entry
process
To investigate the role of B5 ST in EEV membrane
dissolution, virus mutants with a modified ST were
generated. The ST is highly acidic with 14 of the 39
residues being aspartic or glutamic acid. These acidic
residues were treated as two clusters, membrane proximal
(ST amino acids 1–19) and membrane distal (ST amino
acids 20–39), and mutations were introduced as shown in
Fig. 3(a). Before determining the effect of mutations on
EEV membrane stability, it was important to characterize
their effect on B5 expression and EEV morphogenesis. B5
expression was confirmed by immunoblotting (Fig. 3b).
WT B5 is 42 kDa, whilst the modified B5 proteins resolved
at between 38 and 41 kDa in SDS-PAGE due to deletion,
substitution or change in pI. The control protein A36 was
expressed by all viruses, including vDB5R.
Fig. 1. Interaction between A34 and B5 and rupture of the EEV
membrane. (a) Recruitment of B5 to EEV requires the A34 protein.
EEV from wild-type , vDA33R and vDA34R viruses were purified by
sucrose density gradient centrifugation, and analysed by immuno-
blotting with Abs against B5, F13 and D8. (b) EEV that lacked either
A34 or B5 is more stable than wild-type strain (WR). Fresh EEV
were incubated with or without IMV-NAb 2D5 (1:2000) for 1 h at
37 6C and the infectivity was measured by plaque assay. The
remaining EEV was stored at 4 6C and retitrated on days 7, 14 and
21. The black bars and asterisks indicate a significant difference
(P,0.01) between the groups, as determinedby Student’s t-test.(c
and d) Ionic polypeptides did not affect EEV membrane integrity.
Fresh EEV was incubated with or without poly-L-aspartic acid (Mr
5000–15000), poly-L-glutamic acid (Mr 2000–15000), poly-D-
lysine (Mr 70000–150000), poly-L-histidine (Mr 5000–250000)
poly-DL-alanine (Mr 1000–5000) and dextran sulphate (positive
control)at5 mgm l
”1 (c)or 250 mgm l
”1 (d)in presence ofmAb2D5
(diluted 1:1000). Samples were incubated for 1 h at 37 6C. The
total infectivity prior to treatment, the infectivity that is resistant to
IMV-NAb, and the infectivity that is resistant to IMV-NAb in the
presence of PA were determined by plaque assay. Results are
expressed as a percentage of infectivity compared with the sample
incubated with anti-IMV NAb. Data shown are the mean±SD of two
experiments (c) or one representative experiment out of three (d). In
all experiments, EEV was also incubated with polyions in the
absence of IMV-Nab to show that the compounds did not affect
infectivity directly (results not shown).
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ability to form plaques (Figs 3c and d) and produce EEV
(Fig. 3e) was studied. vDB5R makes tiny plaques compared
with WT. The plaques formed by vSTD1–19 and vSTD20–
39, lacking either the membrane distal or proximal half of
the stalk region, respectively, were smaller than those made
by WR, but noticeably larger than those of vDB5R. In
contrast, plaques formed by vST2–35ala, vST2–16ala and
vST23–35ala were smaller. vST2–16ala produced plaques of
similar size to those of vDB5R, whereas those of v2–35ala
and vST23–35ala were marginally larger. Collectively, these
data showed that the ST and the associated acidic residues
affect virus plaque size.
Measurement of EEV production by the different mutants
(Fig. 3e) showed that vDB5R produces 5–10-fold less EEV
than WT, as noted previously (Engelstad & Smith, 1993).
Deletion of either half of the B5 ST had little effect on EEV
production, and the EEV titres of vST2–35ala, vST2–16ala
and vST23-35ala were all intermediate between the wild-
type and vDB5R levels. Notably .70% of virus infectivity
in the culture medium of cells infected by each new mutant
was resistant to IMV-NAb and so represented EEV. Actin tail
and CEV formation were studied by immunofluorescence as
described previously (Herrero-Martinez et al., 2005) and
confirmed that vSTD1–19 and vSTD20–39 were similar to
WT, whilst vST2–35ala, vST2–16ala and vST23–35ala
produced actin tails and CEV in reduced amounts (data
not shown). These data show that deletion of either half of
the B5 ST had little effect on virus morphogenesis, whereas a
greater effect was found with alanine substitution of the
acidic residues. The EEV sensitivity of the mutants to GAGs
was investigated by plaque reduction assay (Fig. 3f). HP
disrupted theEEV membranesofvSTD1–19, vSTD20–39 and
vST2–16alasothatthesemutantsweresensitivetoIMV-Nab,
whilst EEV of vST2–35ala and vST23–35ala was resistant to
HP. The results suggest that acidic residues proximal to the
EEV membrane are crucial because the first three mutants
retain membrane-proximal acidic residues, whereas these
residues are eliminated from the last two mutants.
To determine how near to the TM the acidic residues need
to be for EEV membrane disruption, a second panel of
alanine substitution viruses was created in which the acidic
residues near to the TM were changed sequentially to
alanine (Fig. 4a). As before, the expression of these mutant
proteins and the effects of these mutations on plaque size
and EEV formation were characterized. B5 expression was
confirmed by immunoblotting (Fig. 4b), with expression of
the VACV D8 protein as a control. The plaques of these
mutants were 54–71% the size of the WT plaques, but
bigger than vDB5R and vST23–35ala described above (Fig.
4c), and they produced similar amounts of EEV to WT
(Fig. 4d). These mutants also produced actin tails and CEV
at levels similar to WT (data not shown). Incubation of
EEV with HP disrupted the EEV membranes of all these
viruses, except for vST28–35ala, which, like vDB5 and
vST23–35ala, was resistant (Fig. 4e). For this assay IMV-N-
serum was used and this did not neutralize IMV as
efficiently as mAb 2D5. Data shown in Figs 3 and 4 indicate
that an acidic residue within 11 aa of the predicted TM
region of EEV membrane determines the sensitivity of EEV
membrane to GAGs.
Effect of polyanions and polycations on B5–A34
interaction
B5 is acidic with an isoelectric point (pI) of 4.7 whilst A34
is basic (pI 9.6) so the interaction of these proteins
(Rottger et al., 1999) may be electrostatic. If so, their
interaction might be disrupted by charged molecules and
this might contribute to destabilization of the EEV
Fig. 2. Structure of B5 mutant proteins and the inhibition of EEV
infectivity by dextran sulphate (DS) and heparin (HP). (a)
Illustration of B5 mutants. B5 regions are highlighted by thick
lines. (b) Fresh EEV was incubated with medium or medium
containing DS or HP (5 mgm l
”1) in presence of mAb 2D5.
Samples were processed and data re-expressed as described in
Fig. 1. Data shown are the mean±SD of three experiments.
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affected the interaction between A34 and B5, we performed
co-immunoprecipitation experiments using B5–A34 com-
plexes prepared from EEV (Fig. 5a). VACV strain IHD-J
was used because this strain produces higher levels of EEV
(Payne, 1979). B5 was immmunoprecipitated from EEV
lysates with anti-B5 mAb and, as expected, a proportion of
A34 co-precipitated with B5. Incubation with increasing
concentrations of DS (Fig. 5a) or HP (data not shown)
reduced the amount of A34 pulled-down with B5 and
increased A34 in the unbound fraction. This shows that
GAGs disrupt the B5–A34 interaction. Moreover, negative
charge is needed because desulphated HP did not break
A34–B5 interaction (data not shown).
Fig. 3. Mutational analysis of the B5 ST. (a) Mutations incorporated into the B5 ST (amino acids 1–39). (b) Immunoblot of the
B5 and A36 proteins from infected cell lysates. BHK-21 cells were infected at 3 p.f.u. per cell and incubated for 24 h at 37 6C.
The cells were lysed and the proteins were separated by SDS-PAGE (12% gel). (Top) The membrane was probed with anti-B5
mAb 19C2. WT B5 (arrow) is 42 kDa. (Bottom) The membrane was then reprobed with anti-A36 mAb. A36 is approximately
50 kDa (arrow). (c) Plaque phenotype. BS-C-1 cell monolayers were infected and overlaid with DMEM/2.5% FBS/1.5 %
CMC. After a 10 day incubation period at 37 6C, cell monolayers were stained with crystal violet and scanned using a GelDoc
imager. (d) Plaque size comparison. The diameter of 20 plaques of each virus from two independent experiments in (c) was
measured and the percentage plaque size compared with that of WT WR plaques was calculated. (e) EEV titres: BHK-21 cells
were infected at 3 p.f.u. per cell for 24 h and the supernatant was harvested, incubated with mAb 2D5 (diluted 1:2000) for 1 h
at 37 6C and the infectivity was measured by plaque assay. Data shown are the mean±SD of at least three experiments.
(f) Effect of HP on EEV membrane disruption, as in Fig. 2(b).
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also disrupt the B5–A34 complex. Accordingly, we tested
the effect of chitosan, a positively charged carbohydrate
derived from chitin and with structural similarity to GAGs.
This showed that the interaction of A34 and B5 was greatly
reduced by this polycation (Fig. 5b). However, unlike PAs
(Fig. 1), this polycation was unable to rupture the EEV
membrane, because the virions remained resistant to IMV-
NAb (Fig. 5c).
DISCUSSION
Previously, it has been shown that EEV can enter cells
following rupture of the outer membrane induced by
contact with GAGs on the cell surface and that this
phenomenon requires proteins A34 and B5 (Law et al.,
2006). Here we show that the requirement for the A34
protein is indirect and that in its absence considerably less
B5 protein is incorporated into EEV. Similar observations
have been made by others (Earley et al., 2008; Perdiguero
Fig. 4. Mutations in the C-terminal region of the B5 ST affected plaque size, EEV titre and sensitivity to HP. (a) Alanine
substitutions in the B5 ST. (b) Western blot of the B5 and D8 proteins. Infected cell lysates were prepared, processed and
analysed by immunoblotting as in Fig. 3b except that anti-D8 mAb was used. (c) Plaque size analysis as in Fig. 3. (d) EEV
production as in Fig. 3e. The IMV NAb used was the IMV-N-serum (diluted 1:100) rather than mAb 2D5. (e) Effect of HP on
EEV membrane disruption. See Fig. 2(b) for details except that IMV-N serum (1:100) was used instead of 2D5.
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incorporation in the absence of A34, although this was not
commented on (McIntosh & Smith, 1996). Data presented
also demonstrate that the outer membrane of EEV lacking
either B5 or A34 is more stable than that of the WT and,
for vDA34, this is consistent with its resistance to
disruption by polyanions (Law et al., 2006) and interaction
with cell surfaces (Husain et al., 2007). A34-negative EEV
has lower specific infectivity, but freeze–thawing resulted in
an increase in infectivity due to release of IMV (McIntosh
& Smith, 1996). In view of these observations our study of
EEV outer membrane disruption has focussed on B5.
By using a panel of VACV mutants lacking different B5
domains, we showed that the extracellular SCRs and the
CT are dispensable for GAG-mediated membrane rupture.
This implied that the TM and/or ST are required. It
remains unclear whether the TM is involved directly, but
the ST certainly is. This region is highly negatively charged
at neutral pH (14 out of 39 residues are aspartic or
glutamic acid) and data presented show that negative
charges in this region are critical for GAG-mediated
membrane rupture. More specifically, acidic residues
proximal to the viral membrane are important. If either
the membrane proximal or membrane distal half of the ST
is deleted the membrane remains sensitive to GAG-
mediated rupture because in both cases acidic residues
remain close to the virion membrane. However, if the
acidic residues within the membrane-proximal region were
changed to alanines, the membrane became resistant to
GAG-mediated rupture. In contrast, if the membrane distal
acidic residues were mutated to alanines the membrane
remained sensitive. All viruses with a mutated ST produced
plaques smaller than WR and larger, or the same size, as
vDB5R, but plaque size did not correlate with sensitivity to
GAG-mediated membrane rupture. This is evident from
Fig. 3, where vDB5R and vST2–16ala have equivalent sized
plaques, but the EEV differ in the sensitivity to GAG-
mediated membrane rupture. Conversely, vSTD20–39 and
vST2–16ala have differently sized plaques, but the same
sensitivity to membrane rupture. Further mutagenesis
defined how close to the membrane acidic residues need
to be to enable GAG-mediated membrane rupture.
Rupture still occurred if an acidic residue was ¡11
residues from the TM, but not if the distance was 16
residues. Also, the vST28–30ala mutant shows that two
acidic residues close to the membrane are sufficient.
Overall, these results demonstrate that the negative charge
of the B5 ST is critical for membrane rupture.
Given the basic nature of A34 (pI 9.6), electrostatic
interactions with the B5 acidic stalk are possible.
Recently, Perdiguero et al. (2008) showed that interactions
with A34 can be mediated by the extracellular domain of
B5 and also the TM/CT/ST. Our data are consistent with
the latter possibility. In addition, Perdiguero et al. (2008)
and Earley et al. (2008) showed that the extracellular
domain of A34, which contains most of the basic residues,
is responsible for binding to B5. Further mutagenesis and
structural determination of the complex is required to
define precisely how these proteins interact.
An electrostatic interaction between B5 and A34 might be
disrupted by large positive or negative compounds and we
showed that A34 co-precipitation with B5 was decreased by
PAs (e.g. GAGs) and polycations like chitosan (Fig. 5) or
poly-lysine (not shown). However, unlike PAs, the
polycation could not induce membrane rupture and we
propose this is because after it disrupts the A34–B5
Fig. 5. Ionic compounds interfere with the A34–B5 interaction. (a)
GAGs. IHD-J EEV extracts were incubated with protein G beads
with or without cross-linked anti-B5 mAb 19C2 in the presence or
absence of DS. Supernatants (1/40 of the total volume) and
proteins bound to the beads (1/10) were analysed by immuno-
blotting using mouse mAbs against B5 or A34. (b) Polycations.
EEV extracts were incubated with protein G beads or protein G
beads cross-linked to mAb 19C2 in presence or absence of
chitosan (Ct) at 25 mgm l
”1. Chitosan had to be solubilized in 1 M
acetic acid, and so a control incubated with acid alone (Ac.) was
included. Immunoprecipitation, electrophoresis and immunoblot-
ting were performed as in (a). (c) Fresh EEV was incubated with
medium or medium containing chitosan (Ct) at 1, 5 or 25 mgm l
”1
or HP at 5 mgm l
”1 as a control in the presence of IMV-N serum
(1:100). Samples were incubated for 1 h at 37 6C, and virus
infectivity was determined by plaque assay. Data shown are from
one representative experiment out of four.
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negative charge. In contrast, the disruption of the A34–
B5 complex by PAs would leave the negatively charged
residues of B5 exposed close to the membrane. These
membrane-proximal acidic residues are critical for mem-
brane disruption. A model that might explain this
requirement is electrostatic repulsion between the nega-
tively charged B5 stalks and the negatively charged
phospholipid head groups, leading to the destabilization
and rupture of the membrane.
In conclusion, we demonstrate that, without A34, less B5 is
incorporated into the EEV membrane and EEV lacking
either B5 or A34 have more stable outer membranes. The
acidic B5 ST is critical for the rupture of the EEV
membrane and the acidic residues must be within 11 aa of
the virion membrane to induce membrane instability.
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